Dignitana Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 28

Employees

  • Stock Symbol
  • DIGN

Stock Symbol

  • Share Price
  • $0.14
  • (As of Monday Closing)

Dignitana General Information

Description

Dignitana AB is a medical technology company, that develops, produces, and markets The DigniCap Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. Geographically, it derives a majority of revenue from the USA.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Therapeutic Devices
Stock Exchange
STO
Corporate Office
  • Traktorgränden 3
  • 226 60 Lund
  • Sweden
+46 046-16 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dignitana Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.14 $0.14 $0.12 - $0.46 $11.1M 80.5M 50.5K -$0.03

Dignitana Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 13,526 15,809 34,845 61,121
Revenue 8,085 8,097 7,195 6,646
EBITDA (146) (25) (651) (3,356)
Net Income (1,743) (1,634) (2,209) (5,017)
Total Assets 4,179 4,486 5,613 7,885
Total Debt 1,047 1,912 1,751 2,607
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dignitana Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dignitana‘s full profile, request access.

Request a free trial

Dignitana Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dignitana AB is a medical technology company, that develops, produces, and markets The DigniCap Scalp Cooling System. It
Therapeutic Devices
Lund, Sweden
28 As of 2024
000.00
000000000 000.00

000000

onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
00000 0000000 000 00
Alpharetta, GA
00 As of 0000
000
00000 00000 000

000000

rure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat null
00000000000 0000000
Birkerod, Denmark
00 As of 0000
0000
000.00 0000-00-00
0000000000 0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dignitana Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SoftWave Tissue Regeneration Technologies Venture Capital-Backed Alpharetta, GA 00 000 00000 00000 000
Reapplix Venture Capital-Backed Birkerod, Denmark 00 0000 0000000000 0 0000
You’re viewing 2 of 2 competitors. Get the full list »

Dignitana Patents

Dignitana Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4142662-A1 Scalp cooling apparatus, system, and method Pending 30-Apr-2020 0000000000
US-20210338475-A1 Scalp cooling apparatus, system, and method Inactive 30-Apr-2020 0000000000 0
JP-2023524239-A Scalp cooling device, system and method Pending 30-Apr-2020 0000000000
EP-3876881-A1 Scalp cooling apparatus, method, and system Pending 09-Nov-2018 00000000
US-10993830-B2 Scalp cooling apparatus, method, and system Active 09-Nov-2018 A61F7/02 00
To view Dignitana’s complete patent history, request access »

Dignitana Executive Team (16)

Name Title Board Seat
Fredrik Jonsson Chief Executive Officer
Ulf Jönsson Chief Financial Officer
Stella Ramette Director, International Sales & Marketing
Melissa Bourestom Executive
Johan Johansson Vice President of Operations, Research and Development
You’re viewing 5 of 16 executive team members. Get the full list »

Dignitana Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dignitana Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dignitana‘s full profile, request access.

Request a free trial

Dignitana FAQs

  • When was Dignitana founded?

    Dignitana was founded in 2000.

  • Where is Dignitana headquartered?

    Dignitana is headquartered in Lund, Sweden.

  • What is the size of Dignitana?

    Dignitana has 28 total employees.

  • What industry is Dignitana in?

    Dignitana’s primary industry is Therapeutic Devices.

  • Is Dignitana a private or public company?

    Dignitana is a Public company.

  • What is Dignitana’s stock symbol?

    The ticker symbol for Dignitana is DIGN.

  • What is the current stock price of Dignitana?

    As of 22-Jul-2024 the stock price of Dignitana is $0.14.

  • What is the current market cap of Dignitana?

    The current market capitalization of Dignitana is $11.1M.

  • What is Dignitana’s current revenue?

    The trailing twelve month revenue for Dignitana is $8.08M.

  • Who are Dignitana’s competitors?

    SoftWave Tissue Regeneration Technologies and Reapplix are competitors of Dignitana.

  • What is Dignitana’s annual earnings per share (EPS)?

    Dignitana’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »